Printer Friendly

GLAXO INC. NAMES EXECUTIVES TO NEW POSITIONS

 RESEARCH TRIANGLE PARK, N.C., June 3 /PRNewswire/ -- Building on the team work that has fueled Glaxo Inc.'s growth in both sales and research capability, the pharmaceutical company announced today that two senior executives have been named to new positions.
 Robert A. Ingram has been appointed to the newly created position of president and chief operating officer, with responsibility for most functional units of the company, including the sales and marketing organization, the Glaxo Research Institute, technical operations, and the legal, finance and human resources departments. He will report to Charles A. Sanders, M.D., chairman and chief executive officer.
 In the other management change, George J. Morrow has been named group vice president in charge of the Glaxo Pharmaceuticals strategic business unit. In his new position, he will oversee the sales and marketing divisions responsible for gastrointestinal, anti-infective and central nervous system products, as well as the division responsible for managed health care, hospital sales and national accounts. He will report to Ingram.
 The appointment of Ingram to the new post recognizes the outstanding contributions he has made to the company since joining Glaxo in 1990, as well as his increasing responsibilities in its day-to-day operations, Sanders said. It also positions the company well to meet the challenges of the next decade.
 "Our company's success in the environment of the '90s will depend in large measure upon the focus we bring to every element of the organization," Sanders added. "Each area of the company relies on the success of every other area. It's the right time to bring them together under the central direction of a chief operating officer, and it's the next logical step in putting in place the best management team possible for Glaxo."
 Ingram, 50, formerly was Glaxo Inc.'s executive vice president. Before joining Glaxo, he was president of Merck Frosst Canada Inc. He also has held various executive positions at Merrell Dow Pharmaceuticals.
 Morrow, 41, formerly was vice president and general manager of Cerenex Pharmaceuticals, the sales and marketing division responsible for Imitrex(TM), Glaxo's new migraine medicine, and Zofran(R), which fights nausea and vomiting associated with cancer chemotherapy. Before joining Glaxo in January 1992, he held a series of increasingly responsible positions at Merck Sharp and Dohme, including vice president of marketing.
 Both appointments are effective immediately.
 In a separate matter, the company also announced that Thomas W. D'Alonzo, 49, group vice president in charge of the company's Allen & Hanburys strategic business unit and a key strategist in Glaxo's growth over the last 10 years, had resigned to pursue independent interests.
 Glaxo Inc., a subsidiary of London-based Glaxo Holdings p.l.c., researches, develops and markets prescription medicines, including treatments for gastrointestinal, central nervous system, respiratory, infectious, dermatological and cardiovascular diseases.
 -0- 6/3/93
 /CONTACT: Rick Sluder of Glaxo, 919-248-2839/
 (GLX)


CO: Glaxo Inc. ST: North Carolina IN: MTC SU: PER

CM -- CH006 -- 4896 06/03/93 10:41 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:490
Previous Article:AARON RENTS STEPS UP EXPANSION, ACQUIRES MAYO RENTAL STORES IN PHOENIX AND LAS VEGAS
Next Article:RUBBERMAID ANNOUNCES ORGANIZATIONAL CHANGES
Topics:


Related Articles
GLAXO INC. NAMES VICE PRESIDENT AND GENERAL MANAGER OF NEW DIVISION
GLAXO ANNOUNCES ORGANIZATIONAL REALIGNMENT
ALAN STEIGROD NAMED CORTEX PRESIDENT & CHIEF EXECUTIVE OFFICER
INGRAM NAMED GLAXO INC. CEO; SANDERS TO ASSUME POLICY ROLE
ARTHUR M. PAPPAS DEPARTS GLAXO FOR NEW VENTURES
NEW DIRECTOR APPOINTED TO HEAD GLAXO RESEARCH INSTITUTE
DR. CHARLES SANDERS RESIGNS GLAXO INC. CHAIRMANSHIP
ROBERT A. INGRAM NAMED DIRECTOR OF GLAXO WELLCOME PLC
MEDAREX ANNOUNCES THE APPOINTMENT OF RANDALL T. CURNOW, M.D. AS SENIOR VICE PRESIDENT AND MEDICAL DIRECTOR
Robert A. Ingram Named Chief Executive Of Glaxo Wellcome plc

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters